Jyong Biotech Ltd.
MENS
Analytical Summary
Jyong Biotech Ltd. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.
4-Year Financial Trajectory
AnnualBullish Indicators
- Debt to EquityDebt to Equity is in the top quartile (lower is better)
- Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
Bearish Risks
- No bearish risks detected.
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
-50.0%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
33.3%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-54.7%
Weak
Weak
Year-over-year change in net income |
31.4%
Excellent
Excellent
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
17.7%
Good
Good
Year-over-year change in free cash flow |
-39.3%
Weak
Weak
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ |
|---|---|---|---|---|
| FCF / Net Income (x) |
0.65x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.20x
Good
Good
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.59x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
9.0%
Fair
↑
Fair
Improving
Return earned on debt + equity capital invested
Optimal:
> 10%
|
4.4%
Caution
Caution
Return earned on debt + equity capital invested
Optimal:
> 10%
|
6.5%
Caution
Caution
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-12.5%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-32.3%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — |
| Return on Common Equity (%) (%) |
18.8%
Good
↑
Good
Improving
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+25%)
|
8.3%
Caution
Caution
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-45%)
|
12.9%
Fair
Fair
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-14%)
|
— |
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ |
|---|---|---|---|---|
| Debt to Equity (x) |
-0.70x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-217%)
|
— | — | — |
| Interest Coverage (x) |
-7.74x
Weak
↑
Weak
Improving
Operating income divided by interest expense
Optimal:
> 5x
|
-9.22x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
-26.89x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
— |
| Net Debt (USD) | $17.46M | — | — | — |
| Debt / EBITDA (x) |
-6.96x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
— | — | — |
Secondary lens
Benchmark Lens
Compare MENS against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare MENS against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for MENS
Debt to Equity is in the top quartile (lower is better)
Return on Common Equity (%) is in the top quartile
No bearish signals detected
Percentile Rankings
How MENS compares to all companies
Peer Comparison
MENS vs similar peers
Compare MENS with peers
Stack MENS against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 4 quarters